Phenotypic expressions of CCR5-Δ32/Δ32 homozygosity

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 22, Issue 1, 1999, Pages 75-82

  Nguyêñ, Giang T ^a,b   Carrington, Mary ^c   Beeler, Judith A ^d   Dean, Michael ^e   Aledort, Louis M ^f   Blatt, Philip M ^g   Cohen, Alan R ^h   DiMichele, Donna ⁱ   Eyster, M Elaine ^j   Kessler, Craig M ^k   Konkle, Barbara ^l   Leissinger, Cindy ^m   Luban, Naomi ⁿ   O'Brien, Stephen J ^e   Goedert, James J ^a   O'Brien, Thomas R ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c SAIC FREDERICK INC   (United States)

^d CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

^f MOUNT SINAI MEDICAL CENTER   (United States)

^g CHRISTIANA HOSPITAL   (United States)

^h CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

ⁱ WEILL CORNELL MEDICAL CENTER   (United States)

^j PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^k GEORGETOWN UNIVERSITY   (United States)

^l THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^m TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁿ CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

more..

Author keywords

AIDS; CCR5; Chemokine; Chemokine receptors; Epidemiology; Genetics; Hemophilia; Hepatitis C virus; HIV 1; Hypertension; Lymphocytes; Therapy

Indexed keywords

ALANINE AMINOTRANSFERASE; CHEMOKINE RECEPTOR CCR5;

ARTICLE; GENE EXPRESSION; HEMOPHILIA; HEPATITIS C VIRUS; HOMOZYGOSITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEASLES VIRUS; PHENOTYPE; PRIORITY JOURNAL; RECEPTOR BLOCKING;

EID: 0344246934     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199909010-00010     Document Type: Article

References (39)

1. O'Brien TR, Goedert JJ. Chemokine receptors and genetic variability: another leap in HIV-1 research. JAMA 1998;279:317-318.
2. Adams DH, Lloyd AR. Chemokines: leukocyte recruitment and activation cytokines. Lancet 1997;349:490-95.
3. + T cells. Science 1995;270:1811-15.
4. Alkhatib G, Combadiere C, Broder CC, et al. CC CKR5: a RANTES, MIP-1α, MIP-1 receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996;272:1955-8.
5. Choe H, Farzan M, Sun Y, et al. The β-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996;85:1135-48.
6. Deng HK, Liu R, Ellmeier W, et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996;381:661-6.
7. Doranz BJ, Rucker J, Yi Y, et al. A dual-tropic primary HIV-1 isolate that uses fusion and the β-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 1996;85:1149-1158.
8. + cells is mediated by the chemokine receptor CC-CKR5. Nature 1996;381:667-73.
9. Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996;86:367-77.
10. Dean M, Carrington M, Winkler C, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 1996;273:1856-62.
11. Samson M, Libert F, Doranz BJ, et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996;382:722-725.
12. Zimmerman PA, Buckler-White A, Alkhatib G, et al. Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5: studies in populations with contrasting clinical phenotypes, defined racial background and quantified risk. Mol Med 1997;3:23-36.
13. Martinson JJ, Chapman NH, Rees DC, Liu Y-T, Clegg, J.B. Global distribution of the CCR5 gene 32-basepair deletion. Nature Genet 1997;16:100-3.
14. Huang Y, Paxton WA, Wolinsky SM, et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 1996;2:12400-43.
15. O'Brien TR, Winkler C, Dean M, et al. HIV-1 infection in a man homozygous for CCR5 delta 32. Lancet 1997;349:1219.
16. Theodorou I, Meyer L, Magierowska M, Katlama C, Rouzioux, and the Seroco Study Group. HIV-1 infection in an individual homozygous for CCR5Δ32. Lancet 1997;349:1219-20.
17. Biti R, French R, Young J, Bennetts B, Stewart G, Liang T. HIV-1 infection in an individual homozygous for the CCR5 deletion allele. Nat Med 1997;3:252-3.
18. Michael NL, Chang G, Louie LG, et al. The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression. Nat Med 1997;3:338-40.
19. Moore JP. Coreceptors: implications for HIV pathogenesis and therapy. Science 1997;4;276:51-2.
20. Fauci AS. Host factors and the pathogenesis of HIV-induced disease. Nature 1996;384:529-34.
21. Zhou Y, Kurihara T, Ryseck RP, et al. Impaired macrophage function and enhanced T cell-dependent immune response to mice lacking CCR5, the mouse homologue of the major HIV-1 coreceptor. J Immunol 1998;160:4018-25.
22. Cook DN, Beck MA, Coffman TM, et al. Requirement of MIP-1a for an inflammatory response to viral infection. Science 269:1583-5.
23. Stephens IC, Reich DE, Goldstein DB, et al. Dating the origin of the CCR5-delta 32 AIDS-resistance allele by the coalescence of haplotypes. Am J Hum Genet 1998;62:1507-15.
24. Goedert JJ, Kessler CM, Aledort LM, et al. A prospective study of human immunodeficiency virus type 1 infection and the development of AIDS in subjects with hemophilia. N Engl J Med 1989; 321:1141-8.
25. Goedert JJ, Biggar RJ, Melbye M, et al. Effect of T 4 count and cofactors on the incidence of AIDS in homosexual men infected with human immunodeficiency virus. JAMA 1987;257:331-4.
26. Fletcher MA, Baron GC, Ashman MR, Fischl MA, Klimas NG. Use of whole blood methods in assessment of immune parameters in immunodeficiency states. Diagn Clin Immunol 1987;5:69-81.
27. Tollerud DJ, Brown LM, Clark JW, et al. Cryopreservation and long-term liquid nitrogen storage of peripheral blood mononuclear cells for flow cytometry analysis: effects on cell subset proportions and fluorescence intensity. J Clin Lab Anal 1991;5:255-61.
28. + T-lymphocytopenia in HIV seronegative men with hemophilia and sex partners of HIV seropositive men. Am J Hematol 1995;49: 201-6.
29. Albrecht PA, Herman K, Burns GR. Role of virus strain in conventional and enhanced measles plaque reduction neutralization tests. J Virol Methods 1981;3:251-60.
30. Armitage P. Statistical Methods in Medical Research. Oxford: Blackwell Scientific Publications, 1971:396-8.
31. SAS Institute Inc. SAS User's Guide: Statistics, version 5. Cary, NC: SAS Institute Inc., 1985:402-23.
32. Lifton RP. Molecular genetics of human blood pressure variation. Science 1996;272:676-80.
33. Curnow KM, Pascoe L, White PC. Genetic analysis of the human type-1 angiotensin II receptor. Mol Endocrinol 1992;6:1113-18.
34. Houghton M. Hepatitis C viruses. In: Fields BN, Knipe DM, Howley PM, et al. Field's Virology, 3rd ed. Philadelphia: Lippincott-Raven Publishers, 1996:1035-58.
35. Weis JA, Kasper CK. Increased prevalence of hypertension in hemophilia. In: Fratantoni JC, ed. Unsolved Problems in Hemophilia. U.S. Department of Health, Education, and Welfare Publication No. (NIH) 77-108. Washington, DC: U.S. Government Printing Office, 1976:121-8.
36. Rosendaal FR, Briet E, Stibbe J, et al. Haemophilia protects against ischaemic heart disease: a study of risk factors. Br J Haematol 1990;75:525-30.
37. Eyster ME, Whitehurst DA, Catalano AM, et al. Long-term follow-up of hemophiliacs with lymphocytopenia or thrombocytopenia. Blood 1985;66:1317-20.
38. Hassett J, Gjerset GF, Mosley JW, et al. Effect on lymphocyte subsets of clotting factor therapy in human immunodeficiency virus-1-negative congenital clotting disorders. Blood 1993;82: 1351-7.
39. U.S. Centers for Disease Control and Prevention. Measles prevention. MMWR 1989;38(Suppl 9):1-18.